Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Cash & Equivalents (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Cash & Equivalents for 11 consecutive years, with $213.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents changed N/A to $213.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $213.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $213.2 million for FY2025, N/A changed from the prior year.
  • Cash & Equivalents for Q4 2025 was $213.2 million at Crescent Biopharma, up from $133.3 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $213.2 million in Q4 2025, with the low at $5.6 million in Q1 2025.
  • Average Cash & Equivalents over 5 years is $73.0 million, with a median of $59.1 million recorded in 2022.
  • Peak annual rise in Cash & Equivalents hit 825.99% in 2025, while the deepest fall reached 82.06% in 2025.
  • Over 5 years, Cash & Equivalents stood at $90.3 million in 2021, then tumbled by 46.96% to $47.9 million in 2022, then fell by 12.7% to $41.8 million in 2023, then tumbled by 65.56% to $14.4 million in 2024, then surged by 1381.41% to $213.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $213.2 million, $133.3 million, and $5.6 million for Q4 2025, Q3 2025, and Q1 2025 respectively.